原发性肝癌行肝移植前的桥接治疗  

The Bridging Therapy of Hepatocellular Carcinoma before Liver Transplantation

作　　者：张玉[1] 杨炜[1] 

机构地区：[1]重庆医科大学生物医学工程学院,省部共建国家重点实验室培育基地-重庆市超声医学工程重点实验室,重庆市生物医学工程学重点实验室,重庆市400016

出　　处：《微创医学》2014年第6期763-765,750,共4页Journal of Minimally Invasive Medicine

基　　金：重庆市教委项目(合同号:KJ120319);重庆市自然科学基金(合同号:cstc2012jj A10083;cstc2013jcyj A10109)

摘　　要：桥接治疗是原发性肝癌(Hepatocellular Carcinoma,HCC)行肝移植前的主要辅助治疗方式,能有效降低等待肝移植的退出率,减少肝移植术后肿瘤复发率,提高无瘤生存期及总生存期。对于肝移植术的患者,桥接治疗的角色愈发重要,是一种控制肿瘤进展的必要治疗方式。随着各种新技术的开展,桥接治疗的方式越来越多,技术也不断成熟与完善。然而也存在许多亟待解决的问题。本文就桥接治疗的发展现状进行分析并对新技术进行展望,同时对存在的问题提出建议。Bridging therapy is the important adjuvant therapy for hepatocellular carcinoma before liver transplantation,which can decrease the dropout rate and the recurrence rates after liver transplantation,prolonging tumor-free survival and total survival. Bridging therapy has played a more and more important roles in delaying tumor progression for patients waiting for liver transplantation. With the development of technology used for clinical purpose,kinds of bridging therapy have become more mature and perfect. However,some problems still need to be solved. This article aims to analyze the current situation of the development and looking forward to the new technology of bridging therapy,besides,putting forward the proposal to the current problems.

关 键 词：原发性肝癌 桥接治疗 经皮肝动脉栓塞化疗 射频消融 高强度聚焦超声 

分 类 号：R735.7[医药卫生—肿瘤]